Cantor Fitzgerald Reiterates Overweight Rating for Longboard Pharmaceuticals (NASDAQ:LBPH)

Longboard Pharmaceuticals (NASDAQ:LBPH – Get Free Report)‘s stock had its “overweight” rating reissued by stock analysts at Cantor Fitzgerald in a research note issued to investors on Friday, Benzinga reports. They currently have a $60.00 price target on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 178.68% from the stock’s current […]

Related Keywords

Robertw Baird , ,Longboard Pharmaceuticals Company Profile ,Td Asset Management Inc ,Cantor Fitzgerald ,Longboard Pharmaceuticals Stock Performance ,Parkman Healthcare Partners ,Longboard Pharmaceuticals ,Jennison Associates ,News Ratings For Longboard Pharmaceuticals Daily ,Longboard Pharmaceuticals Inc ,Citigroup ,Institutional Investors Weigh In On Longboard Pharmaceuticals ,Polar Capital Holdings Plc ,Platinum Investment Management Ltd ,Analyst Recommendations For Longboard Pharmaceuticals ,Get Free Report ,Capital Holdings Plc ,Investment Management ,Healthcare Partners ,Management Inc ,Longboard Pharmaceuticals Daily ,